Xilio Therapeutics, Inc.
XLO
$8.95
$0.040.45%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 61.17% | 42.36% | 39.84% | 6.87% | 14.21% |
| Total Depreciation and Amortization | -18.12% | -18.26% | -6.27% | -7.16% | -9.07% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -68.64% | -87.72% | -47.52% | 238.48% | 15.86% |
| Change in Net Operating Assets | -229.64% | -140.19% | -20.95% | -54.87% | -15.98% |
| Cash from Operations | -354.67% | -366.86% | 72.84% | 2.82% | 23.16% |
| Capital Expenditure | -52.97% | -1,713.79% | -1,338.89% | -1,330.00% | -1,985.71% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -52.97% | -1,713.79% | -1,338.89% | -1,330.00% | -1,985.71% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 100.00% | 99.90% |
| Issuance of Common Stock | 106.37% | 406.07% | 314.68% | 147.22% | 147.20% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 25.48% | 258.74% | 200.64% | 210.49% | 252.62% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -68.87% | 13.24% | 662.98% | 2,428.60% | 19,609.21% |